{
    "hands_on_practices": [
        {
            "introduction": "The ability of a cytotoxic T lymphocyte (CTL) to find and eliminate a target cell depends not only on the presence of foreign peptides but also on how long those peptides are displayed. This duration, or stability, of the peptide-MHC (pMHC) complex on the cell surface defines the critical 'window of opportunity' for immune recognition. In this practice, we will use a fundamental biophysical model of first-order decay to quantify the persistence of a pMHC class I complex and explore its direct implications for CD8$^+$ T cell activation .",
            "id": "5092217",
            "problem": "A biophysical model for the turnover of cell-surface Major Histocompatibility Complex class I (MHC I)-peptide complexes assumes first-order loss, where the surface count $N(t)$ of complexes decays according to $\\,\\frac{dN}{dt} = -k_{\\mathrm{decay}}\\,N(t)\\,$ with rate constant $k_{\\mathrm{decay}}$. Consider cytotoxic T lymphocyte recognition by Cluster of Differentiation 8 (CD8) T cells, which depends on the persistence of MHC I-peptide complexes on the plasma membrane. Starting from the first-order decay model and the definition of half-life as the time $t$ at which $N(t)$ equals one-half of the initial count $N(0)$, derive an expression for the half-life in terms of $k_{\\mathrm{decay}}$, and then compute the half-life when $k_{\\mathrm{decay}} = 1.5 \\times 10^{-5}\\,\\mathrm{s}^{-1}$. Express your final numerical answer in hours and round your answer to four significant figures. In your reasoning, interpret how this time scale informs the effective window for CD8 T cell recognition of antigen-bearing cells in molecular and immunodiagnostic contexts, assuming recognition probability decreases as the number of surface complexes declines.",
            "solution": "The problem asks for the derivation of the half-life ($t_{1/2}$) for a species undergoing first-order decay, a numerical calculation of this half-life given a specific decay rate constant, and an interpretation of this result in the context of immunology.\n\nThe validation of the problem statement is performed first.\n\n**Step 1: Extract Givens**\n- The governing differential equation for the surface count $N(t)$ is $\\frac{dN}{dt} = -k_{\\mathrm{decay}}\\,N(t)$.\n- This is a first-order loss process.\n- The decay rate constant is denoted by $k_{\\mathrm{decay}}$.\n- The initial count of complexes at time $t=0$ is $N(0)$.\n- The half-life is defined as the time $t$ at which $N(t) = \\frac{1}{2}N(0)$.\n- A specific value for the rate constant is given: $k_{\\mathrm{decay}} = 1.5 \\times 10^{-5}\\,\\mathrm{s}^{-1}$.\n- The final numerical answer should be in hours and rounded to four significant figures.\n- An interpretation is required regarding the time scale's relevance to CD8 T cell recognition.\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientifically Grounded:** The problem is based on the standard model of first-order kinetics, which is a fundamental concept in chemistry, physics, and biology. Its application to the turnover of cell-surface proteins like MHC complexes is a well-established and valid simplification used in quantitative immunology and biophysics. The context of CD8 T cell recognition of MHC I-peptide complexes is factually correct and central to cellular immunology.\n- **Well-Posed:** The problem is well-posed. It provides a first-order ordinary differential equation and sufficient information (the definition of half-life) to derive a unique analytical expression. A specific value for the rate constant is given, allowing for a unique numerical solution. The instructions on units and rounding are clear.\n- **Objective:** The problem is stated using precise, objective, and formal scientific language. There are no subjective or opinion-based claims.\n\n**Step 3: Verdict and Action**\nThe problem is deemed valid as it is scientifically grounded, well-posed, and objective. I will proceed with the solution.\n\nThe solution process involves three parts: deriving the general expression for half-life, calculating the specific numerical value, and interpreting the result.\n\n**Part 1: Derivation of the Half-Life Expression**\nThe turnover of the MHC I-peptide complex is described by the first-order rate law:\n$$\n\\frac{dN}{dt} = -k_{\\mathrm{decay}}N(t)\n$$\nThis is a separable first-order linear ordinary differential equation. We can separate the variables $N$ and $t$:\n$$\n\\frac{dN}{N} = -k_{\\mathrm{decay}}dt\n$$\nTo find the number of complexes $N(t)$ at any time $t$, we integrate both sides. We integrate the left side from the initial count $N(0)$ at time $t=0$ to $N(t)$ at time $t$.\n$$\n\\int_{N(0)}^{N(t)} \\frac{1}{N'} dN' = \\int_{0}^{t} -k_{\\mathrm{decay}} dt'\n$$\nThe integration yields:\n$$\n[\\ln(N')]_{N(0)}^{N(t)} = [-k_{\\mathrm{decay}}t']_{0}^{t}\n$$\n$$\n\\ln(N(t)) - \\ln(N(0)) = -k_{\\mathrm{decay}}t - 0\n$$\nUsing the property of logarithms, $\\ln(a) - \\ln(b) = \\ln(a/b)$, we get:\n$$\n\\ln\\left(\\frac{N(t)}{N(0)}\\right) = -k_{\\mathrm{decay}}t\n$$\nTo solve for $N(t)$, we exponentiate both sides:\n$$\n\\frac{N(t)}{N(0)} = \\exp(-k_{\\mathrm{decay}}t)\n$$\n$$\nN(t) = N(0)\\exp(-k_{\\mathrm{decay}}t)\n$$\nThis equation describes the exponential decay of the MHC I-peptide complexes on the cell surface.\n\nNext, we apply the definition of half-life, $t_{1/2}$, which is the time at which the count of complexes has decreased to half of its initial value, i.e., $N(t_{1/2}) = \\frac{1}{2}N(0)$. Substituting this into the decay equation:\n$$\n\\frac{1}{2}N(0) = N(0)\\exp(-k_{\\mathrm{decay}}t_{1/2})\n$$\nAssuming $N(0) > 0$, we can divide both sides by $N(0)$:\n$$\n\\frac{1}{2} = \\exp(-k_{\\mathrm{decay}}t_{1/2})\n$$\nTo solve for $t_{1/2}$, we take the natural logarithm of both sides:\n$$\n\\ln\\left(\\frac{1}{2}\\right) = \\ln\\left(\\exp(-k_{\\mathrm{decay}}t_{1/2})\\right)\n$$\nUsing the logarithm properties $\\ln(1/x) = -\\ln(x)$ and $\\ln(\\exp(x)) = x$, this simplifies to:\n$$\n-\\ln(2) = -k_{\\mathrm{decay}}t_{1/2}\n$$\nFinally, solving for $t_{1/2}$ gives the general expression for the half-life in a first-order decay process:\n$$\nt_{1/2} = \\frac{\\ln(2)}{k_{\\mathrm{decay}}}\n$$\n\n**Part 2: Numerical Calculation**\nWe are given the decay rate constant $k_{\\mathrm{decay}} = 1.5 \\times 10^{-5}\\,\\mathrm{s}^{-1}$. Substituting this value into the expression for $t_{1/2}$:\n$$\nt_{1/2} = \\frac{\\ln(2)}{1.5 \\times 10^{-5}\\,\\mathrm{s}^{-1}}\n$$\nUsing the approximate value $\\ln(2) \\approx 0.693147$:\n$$\nt_{1/2} \\approx \\frac{0.693147}{1.5 \\times 10^{-5}}\\,\\mathrm{s} \\approx 46209.8\\,\\mathrm{s}\n$$\nThe problem requires the answer in hours. There are $3600$ seconds in one hour ($60\\,\\mathrm{s/min} \\times 60\\,\\mathrm{min/hr}$). We convert seconds to hours:\n$$\nt_{1/2} (\\mathrm{hours}) = \\frac{t_{1/2} (\\mathrm{seconds})}{3600\\,\\mathrm{s/hr}} = \\frac{46209.8\\,\\mathrm{s}}{3600\\,\\mathrm{s/hr}} \\approx 12.83606\\,\\mathrm{hr}\n$$\nRounding this result to four significant figures gives $12.84\\,\\mathrm{hr}$.\n\n**Part 3: Interpretation**\nThe calculated half-life of $12.84$ hours represents the characteristic timescale over which the surface population of a specific MHC I-peptide complex is reduced by half. This has significant implications for immune surveillance by cytotoxic CD8$^{+}$ T cells.\nThe activation of a CD8$^{+}$ T cell and its subsequent killing of a target cell (e.g., a virus-infected cell or a cancer cell) is not an instantaneous event. It requires the T cell to physically encounter the target cell and for its T cell receptor (TCR) to engage with specific MHC I-peptide complexes on the target cell's surface. This engagement must be of sufficient affinity and duration, and often involves the serial engagement of multiple TCRs with multiple MHC I-peptide complexes, to trigger a sustained intracellular signal leading to T cell activation.\n\nA half-life of approximately $13$ hours provides a substantial \"window of opportunity\" for this recognition event to occur. It signifies that the antigenic \"signature\" of a cell—the foreign or aberrant peptide presented by MHC I—is relatively stable and persistent. Once presented, the signal does not vanish quickly. This persistence increases the probability that a patrolling CD8$^{+}$ T cell, which circulates throughout the body, will find the antigen-bearing cell before the signal decays below the threshold required for recognition.\n\nIn molecular and immunodiagnostic contexts, this stability is equally important. For example, techniques like staining with fluorescently-labeled MHC-peptide tetramers are used to identify and quantify antigen-specific T cells in a patient's sample. The inherent stability of the physiological MHC I-peptide interaction, reflected in this long half-life, informs the design of these diagnostic reagents, which must be stable enough to bind specifically and reliably to T cells during the course of an assay. Furthermore, when assessing T cell function ex vivo (e.g., by co-culturing T cells with antigen-presenting cells), the kinetics of antigen presentation and loss, governed by this decay constant, are a critical parameter. A long half-life implies that the stimulus for the T cells remains present over the typical duration of such assays (hours to days), allowing for robust and measurable responses. Conversely, a very short half-life would imply a transient antigenic signal, making both natural immune detection and diagnostic measurement far more challenging.",
            "answer": "$$\n\\boxed{12.84}\n$$"
        },
        {
            "introduction": "Unlike the relatively direct MHC class I pathway, the MHC class II pathway involves a sophisticated 'peptide editing' process to ensure the immune system responds to the most relevant antigens. Within the late endosome, the chaperone molecule HLA-DM acts as a catalyst, selectively removing weakly bound peptides and promoting the loading of high-affinity peptides derived from extracellular pathogens. This exercise provides a quantitative look at this competitive binding environment, allowing you to calculate how HLA-DM's activity enriches the cell surface with stable pMHC II complexes, thereby enhancing the signal for CD4$^+$ T cell activation .",
            "id": "5092202",
            "problem": "A cell surface Major Histocompatibility Complex class II (MHC II) repertoire is shaped by peptide exchange catalyzed by Human Leukocyte Antigen DM (HLA-DM). Consider an endosomal compartment containing two peptide classes that compete for the same MHC II binding sites: a high-affinity class (denoted $H$) and a low-affinity class (denoted $L$). Assume reversible binding under mass-action kinetics with on-rates $k_{\\mathrm{on}}^{H} = k_{\\mathrm{on}}^{L} = 1.0 \\times 10^{5}\\,\\mathrm{M^{-1}\\,s^{-1}}$, peptide concentrations $c_{H} = 1.0 \\times 10^{-7}\\,\\mathrm{M}$ and $c_{L} = 1.0 \\times 10^{-6}\\,\\mathrm{M}$, and high-affinity off-rate $k_{\\mathrm{off}}^{H} = 2.0 \\times 10^{-3}\\,\\mathrm{s^{-1}}$. HLA-DM increases the off-rate of low-affinity binders from $k_{\\mathrm{off}}^{L} = 5.0 \\times 10^{-2}\\,\\mathrm{s^{-1}}$ to $k_{\\mathrm{off}}^{L} = 2.0 \\times 10^{-1}\\,\\mathrm{s^{-1}}$, while leaving other parameters unchanged.\n\nStarting from the reversible binding law and equilibrium mass-action relations, derive the equilibrium fraction of total MHC II molecules occupied by high-affinity peptides both before and after the HLA-DM-mediated change in $k_{\\mathrm{off}}^{L}$. Then, compute the change in this equilibrium occupancy attributable to the increase in $k_{\\mathrm{off}}^{L}$.\n\nExpress your final result as a decimal fraction, and round your final answer to four significant figures. In addition, explain the immunological implications for Cluster of Differentiation 4 (CD4$^+$) T cell activation based on your calculated change in high-affinity occupancy, grounding your reasoning in the kinetics of peptide–MHC II stability and T cell receptor engagement.",
            "solution": "The problem statement is scientifically grounded, well-posed, and provides all necessary information to determine the equilibrium occupancy of Major Histocompatibility Complex class II (MHC II) molecules. Therefore, a solution can be derived.\n\nThe problem describes a competitive binding equilibrium between two peptide classes, high-affinity ($H$) and low-affinity ($L$), for a single type of MHC II molecule ($M$). The reversible binding reactions can be described using mass-action kinetics:\n$$ M + P_H \\rightleftharpoons MH $$\n$$ M + P_L \\rightleftharpoons ML $$\nwhere $P_H$ and $P_L$ represent the free peptides, and $MH$ and $ML$ represent the peptide-MHC II complexes.\n\nAt equilibrium, the rate of association equals the rate of dissociation for each reaction. Let $[M]$, $[P_H]$, $[P_L]$, $[MH]$, and $[ML]$ be the molar concentrations of the respective species at equilibrium. The equilibrium conditions are:\n$$ k_{\\mathrm{on}}^{H} [M] [P_H] = k_{\\mathrm{off}}^{H} [MH] $$\n$$ k_{\\mathrm{on}}^{L} [M] [P_L] = k_{\\mathrm{off}}^{L} [ML] $$\n\nThese relations can be expressed in terms of the dissociation constants, $K_D^H$ and $K_D^L$:\n$$ K_D^H = \\frac{k_{\\mathrm{off}}^{H}}{k_{\\mathrm{on}}^{H}} = \\frac{[M][P_H]}{[MH]} $$\n$$ K_D^L = \\frac{k_{\\mathrm{off}}^{L}}{k_{\\mathrm{on}}^{L}} = \\frac{[M][P_L]}{[ML]} $$\n\nFrom these definitions, we can express the concentrations of the bound complexes in terms of the free MHC II concentration, $[M]$:\n$$ [MH] = \\frac{[M][P_H]}{K_D^H} $$\n$$ [ML] = \\frac{[M][P_L]}{K_D^L} $$\n\nThe total concentration of MHC II molecules, $[M]_{\\mathrm{total}}$, is the sum of the free and bound forms:\n$$ [M]_{\\mathrm{total}} = [M] + [MH] + [ML] $$\nSubstituting the expressions for $[MH]$ and $[ML]$:\n$$ [M]_{\\mathrm{total}} = [M] + \\frac{[M][P_H]}{K_D^H} + \\frac{[M][P_L]}{K_D^L} = [M] \\left( 1 + \\frac{[P_H]}{K_D^H} + \\frac{[P_L]}{K_D^L} \\right) $$\n\nThe problem asks for the equilibrium fraction of total MHC II molecules occupied by high-affinity peptides, denoted as $\\theta_H$. This fraction is defined as:\n$$ \\theta_H = \\frac{[MH]}{[M]_{\\mathrm{total}}} $$\nSubstituting the expressions for $[MH]$ and $[M]_{\\mathrm{total}}$:\n$$ \\theta_H = \\frac{\\frac{[M][P_H]}{K_D^H}}{[M] \\left( 1 + \\frac{[P_H]}{K_D^H} + \\frac{[P_L]}{K_D^L} \\right)} $$\nThe concentration of free MHC II, $[M]$, cancels out, yielding the general formula for fractional occupancy in a competitive system:\n$$ \\theta_H = \\frac{\\frac{[P_H]}{K_D^H}}{1 + \\frac{[P_H]}{K_D^H} + \\frac{[P_L]}{K_D^L}} $$\nThe peptide concentrations $[P_H]$ and $[P_L]$ are given as $c_H$ and $c_L$, respectively.\n\nThe given parameters are:\n- On-rates: $k_{\\mathrm{on}}^{H} = k_{\\mathrm{on}}^{L} = k_{\\mathrm{on}} = 1.0 \\times 10^{5}\\,\\mathrm{M^{-1}\\,s^{-1}}$\n- Peptide concentrations: $c_{H} = 1.0 \\times 10^{-7}\\,\\mathrm{M}$, $c_{L} = 1.0 \\times 10^{-6}\\,\\mathrm{M}$\n- High-affinity off-rate: $k_{\\mathrm{off}}^{H} = 2.0 \\times 10^{-3}\\,\\mathrm{s^{-1}}$\n- Low-affinity off-rate (before HLA-DM): $k_{\\mathrm{off}, \\text{before}}^{L} = 5.0 \\times 10^{-2}\\,\\mathrm{s^{-1}}$\n- Low-affinity off-rate (after HLA-DM): $k_{\\mathrm{off}, \\text{after}}^{L} = 2.0 \\times 10^{-1}\\,\\mathrm{s^{-1}}$\n\nFirst, we calculate the dissociation constants ($K_D$) for each peptide under both conditions.\n$K_D^H = \\frac{k_{\\mathrm{off}}^{H}}{k_{\\mathrm{on}}} = \\frac{2.0 \\times 10^{-3}\\,\\mathrm{s^{-1}}}{1.0 \\times 10^{5}\\,\\mathrm{M^{-1}\\,s^{-1}}} = 2.0 \\times 10^{-8}\\,\\mathrm{M}$\n$K_{D, \\text{before}}^L = \\frac{k_{\\mathrm{off}, \\text{before}}^{L}}{k_{\\mathrm{on}}} = \\frac{5.0 \\times 10^{-2}\\,\\mathrm{s^{-1}}}{1.0 \\times 10^{5}\\,\\mathrm{M^{-1}\\,s^{-1}}} = 5.0 \\times 10^{-7}\\,\\mathrm{M}$\n$K_{D, \\text{after}}^L = \\frac{k_{\\mathrm{off}, \\text{after}}^{L}}{k_{\\mathrm{on}}} = \\frac{2.0 \\times 10^{-1}\\,\\mathrm{s^{-1}}}{1.0 \\times 10^{5}\\,\\mathrm{M^{-1}\\,s^{-1}}} = 2.0 \\times 10^{-6}\\,\\mathrm{M}$\n\nNext, we calculate the dimensionless concentration ratios, $c/K_D$, which determine the competitive balance.\n$\\frac{c_H}{K_D^H} = \\frac{1.0 \\times 10^{-7}\\,\\mathrm{M}}{2.0 \\times 10^{-8}\\,\\mathrm{M}} = 5.0$\n$\\frac{c_L}{K_{D, \\text{before}}^L} = \\frac{1.0 \\times 10^{-6}\\,\\mathrm{M}}{5.0 \\times 10^{-7}\\,\\mathrm{M}} = 2.0$\n$\\frac{c_L}{K_{D, \\text{after}}^L} = \\frac{1.0 \\times 10^{-6}\\,\\mathrm{M}}{2.0 \\times 10^{-6}\\,\\mathrm{M}} = 0.5$\n\nNow we can calculate the fractional occupancy of high-affinity peptides before and after the action of HLA-DM.\n\nBefore HLA-DM catalysis:\n$$ \\theta_{H, \\text{before}} = \\frac{\\frac{c_H}{K_D^H}}{1 + \\frac{c_H}{K_D^H} + \\frac{c_L}{K_{D, \\text{before}}^L}} = \\frac{5.0}{1 + 5.0 + 2.0} = \\frac{5.0}{8.0} = 0.625 $$\n\nAfter HLA-DM catalysis (modeled as an increase in $k_{\\mathrm{off}}^{L}$):\n$$ \\theta_{H, \\text{after}} = \\frac{\\frac{c_H}{K_D^H}}{1 + \\frac{c_H}{K_D^H} + \\frac{c_L}{K_{D, \\text{after}}^L}} = \\frac{5.0}{1 + 5.0 + 0.5} = \\frac{5.0}{6.5} = \\frac{10}{13} \\approx 0.76923 $$\n\nThe change in the equilibrium occupancy of high-affinity peptides is the difference between these two values:\n$$ \\Delta\\theta_H = \\theta_{H, \\text{after}} - \\theta_{H, \\text{before}} = \\frac{10}{13} - \\frac{5}{8} = \\frac{80 - 65}{104} = \\frac{15}{104} \\approx 0.1442307... $$\nRounding to four significant figures as requested, the change is $0.1442$.\n\nImmunological Implications:\nThe calculated increase in high-affinity peptide occupancy from $62.5\\%$ to $76.9\\%$, a net change of $+14.4\\%$, quantitatively demonstrates the critical role of HLA-DM as a peptide editor in shaping the antigen repertoire presented by MHC class II molecules. This process has profound implications for the activation of CD4$^+$ T helper cells.\n\n$1$. **Enrichment of Stable Peptide-MHC II Complexes**: HLA-DM selectively accelerates the dissociation ($k_{\\mathrm{off}}$) of weakly bound peptides from the MHC II binding groove. As shown in the calculation, a four-fold increase in $k_{\\mathrm{off}}^L$ significantly reduces the competitive fitness of the low-affinity peptide (the ratio $c_L/K_D^L$ drops from $2.0$ to $0.5$), allowing the higher-affinity peptide to more successfully occupy the binding sites, despite its lower concentration. This editing enriches the cell surface with MHC II molecules presenting high-affinity peptides.\n\n$2$. **Enhanced T Cell Activation through Signal Stability**: CD4$^+$ T cell activation via the T cell receptor (TCR) is highly sensitive to the stability of the peptide-MHC II (pMHCII) complex. High-affinity peptides form long-lived pMHCII complexes (low $k_{\\mathrm{off}}$). This stability is crucial for two reasons:\n    - It increases the probability of a cognate T cell locating the specific pMHCII on the surface of an antigen-presenting cell (APC).\n    - It allows for sustained engagement with the TCR, which is necessary to exceed the signaling threshold for T cell activation, a concept often described by models of kinetic proofreading or signal summation.\n\n$3$. **Filtering Immunological \"Noise\"**: By removing transiently bound, low-affinity peptides (which are often derived from abundant self-proteins), HLA-DM focuses the immune response on high-affinity peptides, which are more likely to be of foreign (pathogenic) origin. This quality control mechanism ensures that the APC presents a clear, potent, and unambiguous signal to the adaptive immune system, preventing anergy from suboptimal stimuli and reducing the potential for autoimmunity while promoting a robust and effective response against pathogens.\n\nIn conclusion, the HLA-DM-mediated increase in high-affinity pMHCII occupancy directly translates to a more immunogenic cell surface, primed for potent and specific activation of CD4$^+$ T cells, which is a cornerstone of an effective adaptive immune response.",
            "answer": "$$\\boxed{0.1442}$$"
        },
        {
            "introduction": "A central challenge in immunology and vaccinology is identifying the precise protein fragments, or epitopes, that trigger an immune response. This final practice moves from foundational principles to a direct application, simulating the process of epitope discovery. You will apply your knowledge of allele-specific binding motifs to predict the most likely T-cell epitopes from a pathogenic protein sequence and then outline a rigorous experimental strategy to validate these candidates, a workflow that is fundamental to modern immunodiagnostics and vaccine development .",
            "id": "5092278",
            "problem": "An intracellular pathogen-derived protein fragment is expressed in human cells that are positive for Human Leukocyte Antigen (HLA)-A*$02$:$01$, a class I allele within the Major Histocompatibility Complex (MHC). You are given the following contiguous amino acid sequence from the pathogen protein: MGHLLVAVILTLLAGVAFSVTQLANR. For MHC class I, antigenic peptides are typically between $8$ and $10$ amino acids, with allele-specific anchor residues constraining binding. For HLA-A*$02$:$01$, experimentally established motifs favor hydrophobic residues at position $2$ and at the carboxyl-terminal position of the peptide. Your tasks are to: (i) select the most plausible top three $9$-mer epitope candidates from the given sequence for HLA-A*$02$:$01$ presentation based on these motif constraints and general principles of MHC class I processing, and (ii) outline a rigorous validation plan that includes both a direct binding assay to HLA-A*$02$:$01$ and a downstream T cell detection step using HLA-A*$02$:$01$ tetramers on Cluster of Differentiation (CD)$8^+$ T cells. Assume that the protein is synthesized in the cytosol, processed by the proteasome, transported by the Transporter associated with Antigen Processing (TAP) into the endoplasmic reticulum, and loaded onto MHC class I.\n\nWhich option best satisfies both the epitope selection and the validation plan criteria?\n\nA. Peptides: LLVAVILTL; VILTLLAGV; LLAGVAFSV. Validation: Perform a soluble HLA-A*$02$:$01$ binding competition assay with purified heavy chain and $\\beta_2$-microglobulin ($\\beta_2$m) to determine $\\mathrm{IC}_{50}$ values across a peptide titration, plus an HLA-A*$02$:$01$ stabilization assay on TAP-deficient T$2$ cells; then generate HLA-A*$02$:$01$–peptide tetramers and stain CD$8^+$ T cells from HLA-A*$02$:$01$-matched donor Peripheral Blood Mononuclear Cells (PBMC), with peptide-pulsed and irrelevant-peptide controls.\n\nB. Peptides: VILTLLAGVAFSVTQ; LLAGVAFSVTQLAN; MGHLLVAVILTLLA (all $15$-mers). Validation: Use an HLA-DR binding assay to measure class II peptide binding and stain CD$4^+$ T cells with HLA-DR tetramers from HLA-DRB$1$*$01$:$01$ donors.\n\nC. Peptides: MGHLLVAVI; GHLLVAVIL; HLLVAVILT. Validation: Evaluate peptide immunogenicity by enzyme-linked immunosorbent assay against serum antibodies and use B cell tetramers to detect antigen-specific B cells in PBMC.\n\nD. Peptides: ILTLLAGVA; GVAFSVTQL; LVAVILTLL. Validation: Quantify peptide interactions by Surface Plasmon Resonance (SPR) using a soluble T Cell Receptor (TCR) flowed over immobilized peptide, then stain CD$4^+$ T cells with HLA-A*$02$:$01$ tetramers.\n\nE. Peptides: LLVAVILTL; LLAGVAFSV; GVAFSVTQL. Validation: Measure binding to soluble HLA-A*$24$:$02$ and perform tetramer staining with HLA-A*$24$:$02$ tetramers on HLA-A*$24$:$02$ donor PBMC, using the same peptides.\n\nSelect the single best option.",
            "solution": "We proceed from first principles of the MHC class I pathway and established HLA-A*$02$:$01$ binding motifs.\n\nFoundational facts and reasoning base:\n- MHC class I molecules typically present endogenous peptides of length $8$–$10$ amino acids generated by proteasomal cleavage, transported into the endoplasmic reticulum by the Transporter associated with Antigen Processing (TAP), and loaded onto class I molecules in the peptide-loading complex.\n- The HLA-A*$02$:$01$ binding groove constraint produces an allele-specific motif with dominant anchors at peptide position $2$ and at the peptide carboxyl terminus (position $9$ for a $9$-mer). Hydrophobic residues (commonly leucine, isoleucine, valine, methionine) are favored at position $2$, and hydrophobic residues (commonly leucine, valine, alanine, isoleucine) are favored at the peptide C terminus. These anchors dominate binding energetics. Other positions modulate binding but are less dominant, and proline or charged residues at anchors are generally disfavored.\n- Validation should first quantify peptide binding to HLA-A*$02$:$01$ (e.g., soluble binding competition to obtain $\\mathrm{IC}_{50}$ or cell-surface stabilization on TAP-deficient T$2$ cells), and then demonstrate antigen-specific CD$8^+$ T cells via HLA-A*$02$:$01$–peptide tetramer staining in HLA-A*$02$:$01$-matched donors, with appropriate negative and positive controls.\n\nStep $1$: Enumerate all possible $9$-mer peptides from the given sequence and evaluate anchors.\n\nGiven sequence (indices for clarity): M(1) G(2) H(3) L(4) L(5) V(6) A(7) V(8) I(9) L(10) T(11) L(12) L(13) A(14) G(15) V(16) A(17) F(18) S(19) V(20) T(21) Q(22) L(23) A(24) N(25) R(26).\n\nAll $9$-mers (start–end indices in parentheses), with position-$2$ and position-$9$ residues assessed:\n- MGHLLVAVI (1–9): position $2$ = G (disfavored), position $9$ = I (favored). Net: suboptimal.\n- GHLLVAVIL (2–10): position $2$ = H (disfavored), position $9$ = L (favored). Net: suboptimal.\n- HLLVAVILT (3–11): position $2$ = L (favored), position $9$ = T (disfavored). Net: suboptimal.\n- LLVAVILTL (4–12): position $2$ = L (favored), position $9$ = L (favored). Net: strong.\n- LVAVILTLL (5–13): position $2$ = V (favored), position $9$ = L (favored). Net: strong.\n- VAVILTLLA (6–14): position $2$ = A (neutral to disfavored), position $9$ = A (acceptable but weaker). Net: moderate to weak.\n- AVILTLLAG (7–15): position $2$ = V (favored), position $9$ = G (disfavored). Net: suboptimal.\n- VILTLLAGV (8–16): position $2$ = I (favored), position $9$ = V (favored). Net: strong.\n- ILTLLAGVA (9–17): position $2$ = L (favored), position $9$ = A (acceptable but weaker than L/V). Net: moderate to strong.\n- LTLLAGVAF (10–18): position $2$ = T (disfavored), position $9$ = F (less typical for HLA-A*$02$:$01$). Net: suboptimal.\n- TLLAGVAFS (11–19): position $2$ = L (favored), position $9$ = S (disfavored). Net: suboptimal.\n- LLAGVAFSV (12–20): position $2$ = L (favored), position $9$ = V (favored). Net: strong.\n- LAGVAFSVT (13–21): position $2$ = A (disfavored), position $9$ = T (disfavored). Net: weak.\n- AGVAFSVTQ (14–22): position $2$ = G (disfavored), position $9$ = Q (disfavored). Net: weak.\n- GVAFSVTQL (15–23): position $2$ = V (favored), position $9$ = L (favored). Net: strong.\n- VAFSVTQLA (16–24): position $2$ = A (disfavored), position $9$ = A (acceptable). Net: weak to moderate.\n- AFSVTQLAN (17–25): position $2$ = F (disfavored for the P$2$ pocket of A*$02$:$01$), position $9$ = N (disfavored). Net: weak.\n- FSVTQLANR (18–26): position $2$ = S (disfavored), position $9$ = R (disfavored). Net: weak.\n\nFrom anchor analysis, the strongest candidates are LLVAVILTL (4–12), LVAVILTLL (5–13), VILTLLAGV (8–16), LLAGVAFSV (12–20), and GVAFSVTQL (15–23). Among these, those with both anchors being strongly preferred (L/V at the C terminus rather than A) and with no obvious internal counter-features are particularly compelling. A reasonable top three set is:\n- LLVAVILTL\n- VILTLLAGV\n- LLAGVAFSV\nEach has a favored residue at position $2$ (L, I, L respectively) and a favored residue at position $9$ (L, V, V respectively).\n\nStep $2$: Define a rigorous validation plan that includes both binding assays and tetramer staining.\n- Binding assays appropriate for HLA-A*$02$:$01$ include: (i) a soluble binding competition assay using purified HLA-A*$02$:$01$ heavy chain and $\\beta_2$-microglobulin ($\\beta_2$m) to reconstitute the peptide–MHC complex in vitro, with a labeled high-affinity reference peptide to derive $\\mathrm{IC}_{50}$ values across a peptide titration; and/or (ii) a stabilization assay on TAP-deficient T$2$ cells, where peptide-induced stabilization of surface HLA-A*$02$:$01$ is quantified by flow cytometry. These directly interrogate peptide–HLA binding or stabilization.\n- Tetramer staining: Generate HLA-A*$02$:$01$–peptide tetramers labeled with a fluorophore and stain CD$8^+$ T cells from HLA-A*$02$:$01$-matched donors’ Peripheral Blood Mononuclear Cells (PBMC). Include negative controls (irrelevant peptide tetramer, HLA-mismatched donors) and, if possible, peptide-pulsed autologous antigen-presenting cells to enrich and detect low-frequency T cells. Positive tetramer staining supports antigen-specific CD$8^+$ T cell recognition.\n\nOption-by-option analysis:\n\nA. Peptides: LLVAVILTL; VILTLLAGV; LLAGVAFSV. These match the top-three derived above based on anchors. Validation includes a soluble binding competition with purified HLA-A*$02$:$01$/$\\beta_2$m to obtain $\\mathrm{IC}_{50}$, a T$2$ stabilization assay, and HLA-A*$02$:$01$ tetramer staining of CD$8^+$ T cells from HLA-A*$02$:$01$-matched PBMC with appropriate controls. This is allele-appropriate, mechanistically sound, and rigorous. Verdict — Correct.\n\nB. Peptides are $15$-mers, which are typical of MHC class II, not class I; moreover, validation pivots to HLA-DR binding and CD$4^+$ T cells with HLA-DR tetramers. This targets MHC class II rather than HLA-A*$02$:$01$ class I. Verdict — Incorrect.\n\nC. Peptides: MGHLLVAVI; GHLLVAVIL; HLLVAVILT. Anchor analysis shows only one anchor satisfied in several cases (e.g., first has position $2$ = G, second has position $2$ = H, third has position $9$ = T), making them inferior to the best candidates. Validation uses antibody-based enzyme immunoassay and B cell tetramers, which interrogate humoral rather than CD$8^+$ T cell responses and do not measure peptide–HLA-A*$02$:$01$ binding. Verdict — Incorrect.\n\nD. Peptides: ILTLLAGVA (position $9$ = A, weaker C-terminal anchor), GVAFSVTQL (good), LVAVILTLL (good). At least one peptide is weaker relative to top picks, but more importantly, the validation employs Surface Plasmon Resonance (SPR) with a soluble T Cell Receptor (TCR) flowed over immobilized peptide, which does not directly measure peptide–HLA binding affinity or stability; TCR binds peptide–MHC complexes, not free peptide. It then proposes staining CD$4^+$ T cells with HLA-A*$02$:$01$ tetramers, which target CD$8^+$ T cells; CD$4^+$ T cells recognize class II. Verdict — Incorrect.\n\nE. Peptides include strong candidates, but the validation uses HLA-A*$24$:$02$ reagents and donors, which are mismatched to HLA-A*$02$:$01$ and will not provide meaningful allele-specific binding or T cell detection for HLA-A*$02$:$01$. Verdict — Incorrect.\n\nTherefore, option A uniquely satisfies both accurate epitope selection under HLA-A*$02$:$01$ motif constraints and a rigorous, allele-appropriate validation plan incorporating binding assays and tetramer staining of CD$8^+$ T cells.",
            "answer": "$$\\boxed{A}$$"
        }
    ]
}